asciminib (Rx)

Brand and Other Names:Scemblix
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablets

  • 20mg
  • 40mg

Chronic Myeloid Leukemia

Previously treated patients

  • Indicated for Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) in adults previously treated with ≥2 tyrosine kinase inhibitors (TKIs)
  • 80 mg PO qDay OR 40 mg PO q12hr
  • Continue until disease progression or unacceptable toxicity occurs

Patients with T3151 mutation

  • Indicated for Ph+ CML in CP in adults with the T315I mutation
  • 200 mg PO q12hr
  • Continue until disease progression or unacceptable toxicity occurs

Dosage Modifications

Dosage reductions for adverse reactions

  • First dose reduction
    • Previously treated Ph+ CP-CML: 40 mg PO qDay OR 20 mg PO q12hr
    • Ph+ CP-CML with T315I: 160 mg q12hr
Permanently discontinue
  • All patients: Unable to tolerate first dose reduction

Thrombocytopenia and/or neturopenia

ANC <1x 10^9/L and/or platelets <50x 10^9/L
  • Withhold until ANC ≥1x 109/L and/or platelets ≥50x 109/L
  • Resolved within 2 weeks: Resume at starting dose
  • Resolved >2 weeks: Resume at reduced dose
  • If recurs, withhold until ANC ≥1x 109/L and/or platelets ≥50x 109/L, then resume at reduced dose

Asymptomatic amylase and/or lipase elevations

  • Elevation >2x ULN
    • Withhold until <1.5x ULN
    • If resolved, resume at reduced dose
    • If not resolved, permanently discontinue, and perform diagnostic tests to exclude pancreatitis
    • If recurs at reduced dose, permanently discontinue

Nonhematologic adverse reactions

  • Grade ≥3: Withhold until Grade ≤1; once resolved, resume at reduced dose
  • If not resolved, permanently discontinue

Renal impairment

  • Mild-to-severe (eGFR 15-89 mL/min/1.73 m2, not requiring dialysis): No dosage adjustment necessary

Hepatic impairment

  • Mild-to-severe (any total bilirubin and any AST): No dosage adjustment necessary

Dosing Considerations

Females of reproductive potential: Verify pregnancy status before initiating

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and asciminib

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (1)

                • warfarin

                  asciminib will increase the level or effect of warfarin by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor.

                Minor (0)

                  Previous
                  Next:

                  Adverse Effects

                  >10%

                  All grades

                  • Previously treated Ph+ CP-CML
                    • Platelet count decreased (46%)
                    • Triglycerides increased (44%)
                    • Neutrophil count decreased (39%)
                    • Hemoglobin decreased (35%)
                    • Creatine kinase increased (27%)
                    • Upper respiratory tract infection (26%)
                    • ALT increased (23%)
                    • Musculoskeletal pain (22%)
                    • Headache (19%)
                    • AST increased (19%)
                    • Uric acid increased (19%)
                    • Lymphocyte count decreased (18%)
                    • Fatigue (17%)
                    • Rash (17%)
                    • Phosphate decreased (17%)
                    • Lipase increased (14%)
                    • Calcium corrected decreased (14%)
                    • Creatinine increased (14%)
                    • Hypertension (13%)
                    • Arthralgia (12%)
                    • Diarrhea (12%)
                    • Nausea (12%)
                    • Amylase increased (12%)
                    • Bilirubin increased (12%)
                    • Cholesterol increased (11%)
                  • Ph+ CP-CML with T3151 mutation
                    • ALT increased (48%)
                    • Potassium increased (48%)
                    • Triglycerides increased (46%)
                    • Lipase increased (46%)
                    • Hemoglobin decreased (44%)
                    • Neutrophil count decreased (44%)
                    • Musculoskeletal pain (42%)
                    • Lymphocyte count decreased (42%)
                    • Phosphate decreased (40%)
                    • Uric acid increased (40%)
                    • AST increased (35%)
                    • Calcium corrected decreased (33%)
                    • Fatigue (31%)
                    • Creatinine increased (31%)
                    • Amylase increased (29%)
                    • Nausea (27%)
                    • Rash (27%)
                    • Platelet count decreased (25%)
                    • Bilirubin increased (23%)
                    • Diarrhea (21%)
                    • Vomiting (19%)
                    • Headache (19%)
                    • Arthralgia (17%)
                    • Cough (15%)
                    • Hemorrhage (15%)
                    • Cholesterol increased (15%)
                    • Pruritus (13%)
                    • Hypertension (13%)
                    • Upper respiratory tract infection (13%)
                    • Alkaline phosphate increased (13%)

                  Grade 3 or 4

                  • Previously treated Ph+ CP-CML
                    • Platelet count decreased (24%)
                    • Neutrophil count decreased (17%)
                  • Ph+ CP-CML with T3151 mutation
                    • Lipase increased (21%)
                    • Neutrophil count decreased (15%)
                    • Platelet count decreased (15%)

                  1-10%

                  • All grades

                  • Previously treated Ph+ CP-CML
                    • Abdominal pain (10%)
                    • Potassium decreased (10%)
                    • Cough (<10%)
                    • Dyspnea (<10%)
                    • Pleural effusion (<10%)
                    • Dizziness (<10%)
                    • Peripheral neuropathy (<10%)
                    • Edema (<10%)
                    • Pyrexia (<10%)
                    • Vomiting (<10%)
                    • Constipation (<10%)
                    • Dyslipidemia (<10%)
                    • Decreased appetite (<10%)
                    • Pruritus (<10%)
                    • Urticaria (<10%)
                    • Lower respiratory tract infection (<10%)
                    • Influenza (<10%)
                    • Urinary tract infection (<10%)
                    • Pneumonia (<10%)
                    • Hemorrhage (<10%)
                    • Arrhythmia (including electrocardiogram QT prolonged) (<10%)
                    • Palpitations (<10%)
                    • Cardiac failure congestive (<10%)
                    • Vision blurred (<10%)
                    • Dry eye (<10%)
                    • Hypothyroidism (<10%)
                    • Febrile neutropenia (<10%)
                  • Ph+ CP-CML with T3151 mutation
                    • Constipation (<10%)
                    • Pancreatitis (<10%)
                    • Pyrexia (<10%)
                    • Dizziness (<10%)
                    • Peripheral neuropathy (<10%)
                    • Pneumonia (<10%)
                    • Lower respiratory tract infection (<10%)
                    • Dyspnea (<10%)
                    • Pleural effusion (<10%)
                    • Dry eye (<10%)
                    • Vision blurred (<10%)
                    • Arrhythmia (<10%)
                    • Palpitations (<10%)
                    • Cardiac failure congestive (<10%)
                    • Decreased appetite (<10%)
                    • Dyslipidemia (<10%)
                    • Urticaria (<10%)

                  Grade 3 or 4

                  • Previously treated Ph+ CP-CML
                    • Hypertension (6%)
                    • Uric acid (6%)
                    • Phosphate decreased (6%)
                    • Triglycerides increased (5%)
                    • Lipase increased (3.9%)
                    • Musculoskeletal pain (2.6%)
                    • Creatinine kinase increased (2.6%)
                    • Hemoglobin decreased (2%)
                    • Lymphocyte count decreased (2%)
                    • AST increased (1.9%)
                    • Headache (1.9%)
                    • Amylase increased (1.3%)
                  • Ph+ CP-CML with T3151 mutation
                    • Amylase increased (10%)
                    • Abdominal pain (8%)
                    • Hypertension (8%)
                    • Vomiting (6%)
                    • Phosphate decreased (6%)
                    • ALT increased (6%)
                    • Edema (4.2%)
                    • Musculoskeletal pain (4.2%)
                    • Uric acid increased (4.2%)
                    • Hemoglobin decreased (4.2%)
                    • Lymphocyte count decreased (4.2%)
                    • Fatigue (2.1%)
                    • Diarrhea (2.1%)
                    • Hemorrhage (2.1%)
                    • Headache (2.1%)
                    • Potassium increased (2.1%)
                    • Triglycerides increased (2.1%)
                    • AST increased (2.1%)

                  <1%

                  Grade 3 or 4

                  • Previously treated Ph+ CP-CML
                    • Upper respiratory tract infection (0.6%)
                    • Fatigue (0.6%)
                    • Rash (0.6%)
                    • Nausea (0.6%)
                    • ALT increase (0.6%)
                  Previous
                  Next:

                  Warnings

                  Contraindications

                  None

                  Cautions

                  Thrombocytopenia, neutropenia, and anemia occurred; perform complete blood cell counts every 2 weeks for the first 3 months of treatment and monthly thereafter or as clinically indicated; monitor for signs and symptoms of myelosuppression; advise patients to immediately report fever, any suggestion of infection, or signs or symptoms suggestive of bleeding or easy bruising

                  Hypertension occurred; monitor and manage hypertension using standard antihypertensive therapy during treatment as clinically indicated; advise patients to contact healthcare provider for elevated blood pressure or if symptoms of hypertension occur including confusion, headache, dizziness, chest pain, or shortness of breath

                  Hypersensitivity reactions (eg, rash, edema, bronchospasm) reported; monitor for signs and symptoms of hypersensitivity and initiate appropriate treatment as clinically indicated

                  Based on findings from animal studies and its mechanism of action, fetal harm may occur when administered to pregnant females

                  Pancreatitis

                  • Pancreatitis reported
                  • Assess serum lipase and amylase levels monthly during treatment or as clinically indicated; monitor for signs and symptoms of pancreatic toxicity
                  • Perform more frequent monitoring in patients with history of pancreatitis
                  • If lipase and amylase elevation are accompanied by abdominal symptoms, temporarily withhold therapy, and consider appropriate diagnostic tests to exclude pancreatitis
                  • Inform patients to report to healthcare professional symptoms of pancreatitis, including nausea, vomiting, severe abdominal pain, or abdominal discomfort

                  Cardiovascular toxicity

                  • Cardiovascular toxicity (including ischemic cardiac and CNS conditions, arterial thrombotic and embolic conditions) and cardiac failure occurred
                  • Cardiovascular toxicity occurred in patients with preexisting cardiovascular conditions or risk factors, and/or prior exposure to multiple TKIs
                  • Arrhythmia, including QTc prolongation, occurred
                  • Monitor patients with history of cardiovascular risk factors for cardiovascular signs and symptoms; initiate appropriate treatment as clinically indicated
                  • Cardiac electrophysiology testing showed asciminib does not cause a large mean increase in QTc interval (ie, >20 msec) at maximum dose (200 mg BID); based on available clinical data, small mean QTc increase (<10 msec) cannot be excluded

                  Drug interaction overview

                  • CYP3A4 substrate
                  • Inhibitor of CYP3A4, CYP2C9, and P-glycoprotein (P-gp)
                  • Strong CYP3A4 inhibitors
                    • Closely monitor for adverse reactions, especially in patients treated at 200 mg q12hr
                    • Strong CYP3A4 inhibitor increases both plasma concentrations and risk of toxicities of asciminib
                  • Itraconazole oral solution containing hydroxypropyl-β-cyclodextrin
                    • Avoid coadministration
                    • Itraconazole oral solution containing hydroxypropyl-β-cyclodextrin decreases asciminib plasma concentration and efficacy
                  • Sensitive CYP3A4 substrates
                    • 80 mg/day dosing: Closely monitor for adverse reactions
                    • 200 mg q12hr dosing: Avoid coadministration
                    • Asciminib increases plasma levels of sensitive CYP3A4 substrates and risk of adverse reactions of these substrates
                  • Sensitive CYP2C9 substrates
                    • Avoid coadministration
                    • 80 mg/day-dosing: If coadministration unavoidable, consider reducing CYP2C9 substrate dosage as recommended in its prescribing information
                    • 200 mg q12hr-dosing: If coadministration unavoidable, consider alternative therapy with non-CYP2C9 substrate
                    • Asciminib increases plasma levels and risk of adverse reactions of sensitive CYP2C9 substrates
                  • Sensitive P-gp substrates
                    • Closely monitor for adverse reactions of P-gp substrates
                    • Asciminib increases the plasma concentrations and risk of adverse reactions of P-gp substrates
                  Previous
                  Next:

                  Pregnancy & Lactation

                  Pregnancy

                  Based on animal studies and the mechanism of action, embryofetal harm may occur when administered to pregnant females

                  There are no available data on use in pregnant females to evaluate any drug-associated risks

                  Verify pregnancy status of females of reproductive potential before initiating therapy

                  Contraception

                  • Females of reproductive potential: Use effective contraception during treatment and for 1 week after last dose

                  Infertility

                  • Based on animal studies, fertility may be impaired in females of reproductive potential; reversibility on the effect on fertility is unknown

                  Animal data

                  • Pregnant rats
                    • Maternal toxicity occurred at 600 mg/kg/day, resulting in early termination of the dose group
                    • Adverse embryofetal findings were observed at 25 and 150 mg/kg; no maternal toxicities occurred
                    • Increases in fetal weights at 25 and 150 mg/kg/day were observed
                    • Malformations were evident at 150 mg/kg and included cleft palate, anasarca (edema), and cardiac abnormalities
                  • Pregnant rabbits
                    • Maternal toxicity occurred at 300 mg/kg/day, resulting in early termination of the dose group
                    • Adverse embryofetal findings were observed at 50 mg/kg; no maternal toxicities occurred; findings include increases in early resorptions and postimplantation loss, decreases in number of live fetuses, and cardiac malformations

                  Lactation

                  There are no data on presence of asciminib or its metabolites in human milk, effects on breastfed infants, or effects on milk production

                  Advise females not to breastfeed during treatment and for 1 week after last dose

                  Pregnancy Categories

                  A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                  B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                  C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                  D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                  X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                  NA: Information not available.

                  Previous
                  Next:

                  Pharmacology

                  Mechanism of Action

                  ABL/BCR-ABL1 tyrosine kinase inhibitor

                  Binds to ABL myristoyl pockets, which inhibits the ABL1 kinase activity of the BCR-ABL1 fusion protein

                  Absorption

                  Peak plasma time: 2.5 hr

                  Steady-state reached by 3 days

                  Peak plasma concentration

                  • 80 mg qDay: 1,781 ng/mL
                  • 40 mg q12hr: 793 ng/mL
                  • 200mg q12hr: 5,642 ng/mL

                  AUC

                  • 80 mg qDay: 15,112 ng⋅hr/mL
                  • 40 mg q12hr: 5,262 ng⋅hr/mL
                  • 200mg q12hr: 37,547 ng⋅hr/mL

                  Accumulation ratio

                  • 80 mg qDay: 1.3
                  • 40 mg q12hr: 1.65
                  • 200mg q12hr: 1.92

                  Effect of food

                  • High-fat meal (1000 calories, 50% fat): AUC and Cmax decreased by 62% and 68%
                  • Low-fat meal (400 calories, 25% fat): AUC and Cmax decreased by 30% and 35%

                  Distribution

                  • Vd (steady-state): 151 L
                  • Asciminib is the main circulating component in plasma (93% of administered dose)
                  • Protein bound: 97%

                  Metabolism

                  Metabolized by CYP3A4-mediated oxidation, UGT2B7- and UGT2B17-mediated glucuronidation

                  Elimination

                  Clearance: 6.7 L/hr (40 mg q12hr or 80 mg qDay); 4.1 L/hr (200 mg q12hr)

                  Half-life: 5.5 hr (40 mg q12hr or 80 mg qDay); 9 hr (200 mg q12hr)

                  Excretion: Feces (80% [57% unchanged]), urine (11% [2.5% unchanged])

                  Eliminated by biliary secretion via breast cancer–resistant protein

                  Previous
                  Next:

                  Administration

                  Oral Administration

                  Take without food

                  Avoid eating for at least 2 hr before and 1 hr after taking a dose

                  Once-daily dosing: Administer orally about the same time each day

                  Swallow tablets whole; do NOT break, crush, or chew

                  Missed dose

                  • Once-daily dosing regimen: If dose is missed by >12 hr, skip dose and take the next dose as scheduled
                  • Twice-daily dosing regimen: If dose is missed by >6 hr, skip dose and take the next dose as scheduled

                  Storage

                  Tablets: Store at 20-25ºC (68-77ºF); excursions permitted to 15-30ºC (59-86ºF)

                  Dispense and store in original container to protect from moisture

                  Previous
                  Next:

                  Images

                  No images available for this drug.
                  Previous
                  Next:

                  Patient Handout

                  A Patient Handout is not currently available for this monograph.
                  Previous
                  Next:

                  Formulary

                  FormularyPatient Discounts

                  Adding plans allows you to compare formulary status to other drugs in the same class.

                  To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                  Adding plans allows you to:

                  • View the formulary and any restrictions for each plan.
                  • Manage and view all your plans together – even plans in different states.
                  • Compare formulary status to other drugs in the same class.
                  • Access your plan list on any device – mobile or desktop.

                  The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                  Tier Description
                  1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                  2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                  3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                  4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  NC NOT COVERED – Drugs that are not covered by the plan.
                  Code Definition
                  PA Prior Authorization
                  Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                  QL Quantity Limits
                  Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                  ST Step Therapy
                  Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                  OR Other Restrictions
                  Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                  Additional Offers
                  Email to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  Email Forms to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  Previous
                  Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.